Aveo Capital Partners LLC Invests $290,000 in Stryker Co. (NYSE:SYK)

Aveo Capital Partners LLC bought a new position in Stryker Co. (NYSE:SYK - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 805 shares of the medical technology company's stock, valued at approximately $290,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Manchester Capital Management LLC raised its holdings in Stryker by 4.7% in the fourth quarter. Manchester Capital Management LLC now owns 2,612 shares of the medical technology company's stock valued at $940,000 after buying an additional 118 shares during the period. Covenant Asset Management LLC purchased a new position in Stryker in the fourth quarter valued at about $3,873,000. BXM Wealth LLC purchased a new stake in shares of Stryker in the fourth quarter worth about $467,000. PUREfi Wealth LLC purchased a new stake in shares of Stryker during the 4th quarter valued at about $7,846,000. Finally, V Square Quantitative Management LLC boosted its holdings in Stryker by 7.5% in the 4th quarter. V Square Quantitative Management LLC now owns 5,799 shares of the medical technology company's stock worth $2,088,000 after acquiring an additional 403 shares during the period. Institutional investors and hedge funds own 77.09% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on SYK shares. UBS Group upped their target price on shares of Stryker from $366.00 to $370.00 and gave the company a "neutral" rating in a research note on Wednesday, October 30th. StockNews.com cut Stryker from a "buy" rating to a "hold" rating in a research note on Thursday, January 30th. Evercore ISI upped their price target on shares of Stryker from $380.00 to $384.00 and gave the company an "outperform" rating in a report on Wednesday, October 30th. Needham & Company LLC reissued a "buy" rating and set a $442.00 price objective on shares of Stryker in a report on Wednesday, January 29th. Finally, JPMorgan Chase & Co. upped their target price on shares of Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a research note on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $420.68.

Insider Buying and Selling at Stryker

In related news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the business's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.

Stryker Stock Performance

Shares of Stryker stock traded down $2.05 during trading on Thursday, hitting $386.47. 930,252 shares of the stock were exchanged, compared to its average volume of 1,392,508. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The stock's fifty day moving average is $377.69 and its 200 day moving average is $368.08. The stock has a market cap of $147.47 billion, a PE ratio of 49.80, a P/E/G ratio of 2.90 and a beta of 0.96. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the firm earned $3.46 EPS. As a group, sell-side analysts anticipate that Stryker Co. will post 13.49 EPS for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's dividend payout ratio is presently 43.30%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.